Podcasts about Case Western Reserve University

In this episode of the Charity Charged show, Dr. Jacklyn Chisholm, president and CEO of Step Forward, discusses the organization's mission to empower low-income families towards self-sustainability. She shares insights on transforming organizational culture, the importance of trust in leadership, and the challenges of navigating funding in the nonprofit sector.Dr. Chisholm emphasizes the need for nonprofits to balance business acumen with their charitable missions, advocating for a sustainable future for organizations like Step Forward.About Dr. Jacklyn ChisholmA lifelong learner, Dr. Chisholm is a Harvard Business School alumna with additional executive education credentials from the Harvard Kennedy School, Wharton School, and Cornell University. She holds a B.A. in Medical Anthropology, M.A. in Psychological Anthropology, and a Ph.D. in Psychological Anthropology with a focus in Educational Anthropology from Case Western Reserve University.Dr. Chisholm has broken barriers throughout her career, including as the first Vice President of Planning and External Affairs at the Rock and Roll Hall of Fame and Museum, where she led the $13 million construction of its Library and Archives. At Case Western Reserve University, she was the first to hold multiple pioneering roles, including Associate Vice President for Community Partnerships and Director of Community Relations.Her work has earned widespread recognition, including the Crain's Cleveland Business Notable Leader in Philanthropy, Smart Business Progressive Woman Award, YWCA Woman of Achievement, and the Council for Opportunity in Education National TRIO Achiever Award, among many others. A proud Leadership Cleveland alumna, Dr. Chisholm continues to be a trailblazer in education, advocacy, and transformational leadership.About Charity Charge:Charity Charge is a financial technology company serving the nonprofit sector. From the Charity Charge Nonprofit Credit Card to bookkeeping, gift card disbursements, and state compliance, we help mission-driven organizations streamline operations and stay financially strong. Learn more at charitycharge.com.

Welcome to the 6th episode of our BTK/ASGBI series!  During this series, BTK fellow Agnes Premkumar and ASGBI hosts Jared Wohlgemut and Gita Lingam will compare and contrast various aspects of surgery between the United States and the United Kingdom, debating who does what better.  In this episode, we delve into surgical training, current challenges, and hopes for the future of surgical training in the US and the UK. We will be discussing the advent of the EPA curriculum in the US, the current challenge of obtaining a speciality position in the UK, and tips for making the resident to attending/junior faculty transition smoothly. Dr. Jeremy Lipman represents the US while Dr. Phil Pearce represents the UK in this thought-provoking conversation. Dr. Lipman is a colorectal surgeon at the Cleveland Clinic and the director of graduate medical education for all training programs at the Cleveland Clinic. Additionally, he is an Associate Dean for Graduate Medical Education and Professor of Surgery at Case Western Reserve University. He is passionate about surgical training and holds the James E. Sampliner Endowed Chair in Surgical Education.  Dr. Phil Pearce is a consultant in emergency general surgery in Oxford with interests in trauma, complex biliary disease, and most importantly a passion for training. Take a listen and let us know what you think- who does surgical education and training better?  References: Speciality training position in the NHS https://www.ft.com/content/e4b364c3-6a20-42ee-a9a5-ab9eea441c87?utm_source=chatgpt.com https://www.theguardian.com/society/2025/jul/02/nhs-in-england-told-to-slash-recruitment-of-overseas-trained-medics?utm_source=chatgpt.com Surgery job market in the US https://surgpli.com/the-state-of-surgery-as-a-career-in-2025/ EPA curriculum https://www.aamc.org/about-us/mission-areas/medical-education/cbme/core-epas Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

I'm excited to welcome back Jennie Young to the podcast. Jennie is here to talk about dating after divorce and how to protect yourself from getting tangled in the patterns you worked so hard to get yourself out of. She's the creator of the Burned Haystack Dating Method — a sharp and fiercely feminist approach to spotting danger early in the dating process, and the author of the upcoming book Burn the Haystack In our conversation, Jennie and I dig into the realities of dating after divorce: from spotting danger in seemingly “safe” profiles to challenging the patriarchal scripts that keep women waiting to be chosen. Plus, we talk about shifting into the seat of choice, what it looks like to feel genuinely comfortable being single, and how these changes ripple out into raising kids with healthier expectations. ✨ Podcast episodes are available in two formats - audio and video! If you'd like to watch the video version of this episode, you can find it here. What you'll hear about in this episode: Jennie shares her origin story and the ah-ha moment that led to creating The Burned Haystack Dating Method (2:31) The feminist philosophy behind Burned Haystack and how it flips the traditional “pick me” script (5:33) Why green flags can actually be red flags in disguise: from love bombing to performative sensitivity (15:25) The importance of being comfortable (and even happy) being single before re-entering dating (32:44) What the “extinction burst” in the toxic manosphere means, and why starving it of attention is essential (35:09) How to shift the messaging for our kids so they grow up with healthier expectations and values (42:39) Learn more about Jennie Young: Jennie Young is the creator of Burned Haystack Dating Method, a dating method grounded in applied rhetoric and feminist praxis. It is designed to combat many of the challenges of dating in a market that is too frequently mediated by misogynistic and patriarchal structures. She holds a Ph.D. in rhetoric and discourse studies from Case Western Reserve University and a satire writing certificate from Second City Chicago. Her work has been published in McSweeney's, Ms. Magazine, HuffPost, and others and covered by major media outlets such as The New York Times, Newsweek, RollingStone, and others. Resources & Links: ALL NEW: The Divorce Survival Guide Podcast Episodes are Now Available on YouTube! Focused Strategy Sessions with Kate The Divorce Survival Guide Resource BundlePhoenix Rising: A Divorce Empowerment CollectiveKate on InstagramKate on FacebookKate's Substack Newsletter: Divorce Coaching Dispatch Jennie's book Burn the HaystackJennie's Substack, Burned HaystackJennie's website Jennie's Facebook Group Jennie on Instagram Episode 317: Burned Haystack Dating Method with Jennie Young Episode 325: They Helped Me Find Love—Now They're Interviewing Me About It! With Alyssa Dineen and Jennie Young =================== DISCLAIMER:  THE COMMENTARY AND OPINIONS AVAILABLE ON THIS PODCAST ARE FOR INFORMATIONAL AND ENTERTAINMENT PURPOSES ONLY AND NOT FOR THE PURPOSE OF PROVIDING LEGAL OR PSYCHOLOGICAL ADVICE.  YOU SHOULD CONTACT AN ATTORNEY, COACH, OR THERAPIST IN YOUR STATE TO OBTAIN ADVICE WITH RESPECT TO ANY PARTICULAR ISSUE OR PROBLEM. =================== Episode link: https://kateanthony.com/podcast/episode-336-breaking-patterns-choosing-power-dating-after-divorce-with-jennie-young/  

In this episode, Dr. Goutham Rao, Chair of Family Medicine and Community Health at University Hospitals of Cleveland and Case Western Reserve University, shares insights on the global challenges of recruiting primary care physicians. He discusses strategies for making the work more engaging, the role of innovation and AI, and how to inspire future physicians through meaningful connections with patients.

Stanley Bazarek, MD, and Jennifer Sweet, MD, discuss the latest advances in neuromodulation, peripheral nerve surgery, and neuroengineering, highlighting the critical role of multidisciplinary collaboration between UH, Case Western Reserve University, and national research partners in translating these innovations from the lab to patient care. Learn more about Stanley Bazarek, MD Learn more about Jennifer Sweet, MD Learn more about the University Hospitals Research & Education Institute Follow Us on Social:      

Jason Toth was named senior associate vice president for administration for the University of Toledo in January 2019. He oversees the University's Facilities & Construction and Supply Chain offices.In his role, Toth leads the planning, directing, and monitoring of facilities operations and maintenance for the physical plant of the University. He is also responsible for the coordination and management of capital construction projects, aligning them with the University's Strategic and Campus Master Plans. Additionally, Toth leads the supply chain management division which handles University procurement, Shipping/Receiving/Mail Services/Surplus Property, along with the University of Toledo Medical Center's central distribution and linen services areas.Toth joined the University in 2011 as the Director of Facilities/Civil Engineer. He oversaw the re-engineering of the department's Construction Project Management Team. He applied his expertise to streamline processes and create efficiencies resulting in increased customer satisfaction and a reduction to the University's deferred maintenance liability.In 2012 Toth was promoted to University Chief Engineer, in 2013 to Associate Vice President, and in 2019 to Senior Associate Vice President. Under his leadership the departments for which he provides oversight strive to provide exceptional environments, deliver top end service, and promote the University's mission to improve the human condition.Prior to joining UToledo, Toth spent 13+ in the construction management field working for Bostleman Corporation.Toth received his Bachelor of Science in Civil Engineering from Case Western Reserve University. He is a LEED accredited professional and attended the Harvard Graduate School of Education, Institute for Educational Management.Jason has been happily married to his wife Janell for 27+ years.  They have 5 children – Addison, Broc, Carson, Delaney, and Eli (ABCDE) and two adorable grand children (Julia – 5 and Sadie – 2).  In his free time he enjoys walking, hiking, cycling and has been coaching youth sports for nearly 30yrs.

Send us a textEver wonder how your earliest experiences shape your entire worldview? Steve Scheidt knows firsthand. After spending his first five years in Nairobi, Kenya, his return to the United States came with a startling question at the Chicago Zoo: "Why are all the animals behind bars?" Having only known wildlife in their natural habitat, Steve's perspective was forever changed by these formative experiences.From those unique beginnings, Steve shares his journey through athletics, education, and family life that led him to his current role at Case Western Reserve University's Weatherhead School of Management. His story weaves through college rowing practices at dawn, the warmth of Italian family gatherings centered around food, and the unexpected path from journalism student to education professional.The conversation takes a profound turn when Steve reflects on parenting and the accelerating nature of time as we age. "You don't want to be the person saying 'I wish I would have done that,'" he advises, emphasizing the critical importance of being fully present in each moment with loved ones. His observations about how technology affects today's students compared to previous generations offers thought-provoking insights about connection in the digital age.Throughout the episode, Steve's warmth and wisdom shine through, particularly when discussing the value of meaningful relationships and genuine human connection. His final message about kindness and inclusion serves as a powerful reminder that how we treat others ultimately defines our legacy as we measure our lives not in months, but in decades.Join us for this heartfelt conversation about worldview, presence, and the moments that truly matter. Whether you're navigating career choices, parenting challenges, or simply seeking to live more intentionally, Steve's journey offers valuable perspective that will resonate long after the episode ends.Subscribe for exclusive content: https://www.buzzsprout.com/1530455/support Buzzsprout - Let's get your podcast launched!Start for FREETactical BrotherhoodThe Tactical Brotherhood is a movement to support America.Dubby EnergyFROM GAMERS TO GYM JUNKIES TO ENTREPRENEURS, OUR PRODUCT IS FOR ANYONE WHO WANTS TO BE BETTER.ShankitgolfOur goal here at Shankitgolf is for everyone to have a great time on and off the golf courseSweet Hands SportsElevate your game with Sweet Hands Sports! Our sports gloves are designed for champions,Buddy's Beard CareBuddy's Beard Care provides premium men's grooming products at an affordable price.Deemed FitBe a part of our movement to instill confidence motivation and a willingness to keep pushing forwardDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showFollow us on all social mediaX: @mikebonocomedyInstagram: @mikebonocomedy@tiktok: @mikebono_comedianFacebook: @mikebonocomedy

In this episode, Dr. Goutham Rao, Chair of Family Medicine and Community Health at University Hospitals of Cleveland and Case Western Reserve University, shares insights on the global challenges of recruiting primary care physicians. He discusses strategies for making the work more engaging, the role of innovation and AI, and how to inspire future physicians through meaningful connections with patients.

Have you heard about people buying weight loss medications from unregulated sources online? The rise of black market weight loss drugs is putting lives at risk. In this episode, I discuss the concerning trend of people purchasing Retatrutide—a medication still in clinical trials—through illegal channels. Known as the "Godzilla Jab" for its potential power, early studies suggest this drug could help people lose up to 24% of their body weight. I explain what Retatrutide is and how it compares to FDA-approved medications like Ozempic, Wegovy, Zepbound, and Mounjaro. We explore why people take dangerous risks with black market drugs, from social media hype to cost concerns and access issues. Most importantly, I share the serious health and legal risks of buying unregulated medications and provide clear guidelines for safely accessing weight loss treatments through licensed providers. Tune in to learn how to protect yourself and make informed decisions about weight loss medications the safe way.   Episode Highlights: What is Retatrutide The dangers of purchasing unregulated medications online Factors driving people to illegal sources Legal risks of buying unapproved drugs and potential health complications from unregulated substances Safe Medication Practices Understanding that medication works best when combined with healthy eating, physical activity, adequate rest, and emotional support   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

What if the conventional narrative of the 1960s civil rights era, by its very nature, limits the success, legal achievements, and persistence of Black Americans for generations? In Before the Movement: The Hidden History of Black Civil Rights, author Dylan C. Penningroth maintains that the fight for civil rights didn't begin with famous marches and courtroom cases of the 1960s. Instead, his research stretches from the last decades of slavery to the 1970s, and challenges nearly every aspect of our traditional understanding of civil rights history as we know it.rnrnDrawing on long-forgotten sources found in the basements of county courthouses across the nation, Penningroth centers the everyday lives of Black Americans and sheds light on their centuries-long tradition of legal knowledge to assert their rights, protect their families, and shape their communities.rnrnDylan C. Penningroth is a professor of law and Morrison Professor of history at the University of California, Berkeley. He specializes in African American history and legal history and is a MacArthur Fellow. Before the Movement won eleven book prizes and was shortlisted for four more. He is also the author of the award-winning book, The Claims of Kinfolk: African American Property and Community in the Nineteenth-Century South.

Send us a textEver wondered who orchestrates the complex symphony of college athletics? In this riveting conversation with TJ Shelton, Director of Athletics and Chair of the Physical Education Department at Case Western Reserve University, we pull back the curtain on collegiate sports administration and discover the invisible architecture that supports student-athletes.TJ brings a wealth of experience to our discussion, having spent 15 years at Ohio State University before taking the helm at Case Western in 2022. What makes his perspective particularly valuable is his experience across both Division I and Division III athletics, highlighting the unique aspects of each environment. At Case Western, coaches don't just coach—they teach as faculty members, creating a seamless integration between academics and athletics that defines the Division III experience.The conversation takes us through the daily challenges of athletic administration, from coordinating travel for multiple teams to ensuring proper medical support for student-athletes. "You're kind of like officials," TJ explains. "If you're part of the game, then something went wrong." This insight perfectly captures the essence of effective athletic leadership—creating environments where athletes can focus entirely on performance while administrators handle everything else. We explore how hosting NCAA championships requires meticulous planning, from managing team buses to coordinating facilities, all with the goal of allowing student-athletes to "sleep in their own beds" during important competitions.Beyond the logistics, TJ shares heartfelt reflections on how sports build character and prepare young people for life's challenges. As both an administrator and a father, he's witnessed firsthand how athletics instill accountability, teamwork, and work ethic that translate directly to success in academics and careers. For listeners considering colleges for themselves or their children, TJ offers compelliSubscribe for exclusive content: https://www.buzzsprout.com/1530455/support Buzzsprout - Let's get your podcast launched!Start for FREETactical BrotherhoodThe Tactical Brotherhood is a movement to support America.Dubby EnergyFROM GAMERS TO GYM JUNKIES TO ENTREPRENEURS, OUR PRODUCT IS FOR ANYONE WHO WANTS TO BE BETTER.ShankitgolfOur goal here at Shankitgolf is for everyone to have a great time on and off the golf courseSweet Hands SportsElevate your game with Sweet Hands Sports! Our sports gloves are designed for champions,Buddy's Beard CareBuddy's Beard Care provides premium men's grooming products at an affordable price.Deemed FitBe a part of our movement to instill confidence motivation and a willingness to keep pushing forwardDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showFollow us on all social mediaX: @mikebonocomedyInstagram: @mikebonocomedy@tiktok: @mikebono_comedianFacebook: @mikebonocomedy

In episode 139, we chat with Melanie Falls, a member of the National Board of Directors for the Human Rights Campaign (HRC), about the amazing work the organization has done and continues to do.Melanie has been involved in advocacy for the LGBTQ+ community for over thirty-five years. She has worked on the lecture circuit throughout NE Ohio educating about the LGBTQ+ community. She has presented at NEOUCOM, University Hospital's Medical School, Social Work and Counseling Conferences to name a few.She is a founding member of Equality Ohio and served as Board Chair in 2007-2008. A general member of HRC for over ten years, she began active volunteering as a member of the Cleveland Gala Committee moving on to be the Gala Co-Chair for two years. As a member of the Cleveland Steering Committee, she held numerous positions including Steering Committee Co-Chair, Federal Club Tri-Chair and Diversity Equity and Inclusion liaison to the national office.She has been an HRC Federal Club speaker for Cleveland, Columbus and St. Louis. Melanie served as an HRC Governor from 2015 to 2017 and has been on the National Board of Directors since 2017. As a National Director, she has co-chaired the National Public Policy Committee and served on the Board Diversity Committee and Board Development Committee. Melanie is a Licensed Independent Social Worker. She has worked extensively throughout Northeast Ohio in mental health counseling, foster care and adoption. Her expertise is in Trauma Treatment, Women's Mental Health Issues, Marriage and Family therapy and LGBTQIA mental health and relationships concerns. Melanie retired in 2015 as the Executive Director of Applewood Centers, Inc. a child and family Mental health agency. Since retirement from Applewood Centers, Inc. she has been working as a private practitioner at Lifestance Health, a national mental health organization. She has been an adjunct professor and a program consultant at the Mandel School of Applied Social Sciences at Case Western Reserve University. Melanie has been legally married to her wife Tina for twenty-one years. They've been together for thirty years. Together they have raised Melanie's four biological children, two sons and two daughters and have eight grandchildren. Grandparenting is their favorite and cherished pastime. Don't ask them about their grandchildren unless you have a few hours to spare. Their intimate Sunday dinners often number 18.Resources: * Human Rights Campaign: HRC WebsiteConnect with USS:* Substack* Instagram* TikTokThis episode was edited by Kevin Tanner. Learn more about him and his services here:* Website* Instagram Get full access to United SHE Stands at www.unitedshestands.com/subscribe

A local professor from Case Western Reserve University is one of dozens of scientists who are pushing back against a Department of Energy report.

Check out my top picks for skin care here. Download the Free eBook 'Skincare Myths Busted' What do you do when the face in the mirror doesn't match how you feel inside? Welcome to the skin shift that happens in midlife — a direct result of hormonal changes, specifically the drop in estrogen that comes with perimenopause and menopause. And while it's common, it's not talked about enough. Until now. In this episode, I sit down with Dr. Pooja Rambhia, a board-certified dermatologist who's leading the conversation around what's been coined the “menopause makeover.” This is about understanding what's happening in your skin and body during menopause, and how to support both with science, compassion, and the right strategies. From collagen loss to skin laxity to the real reason your products aren't working anymore, we cover it all. We also talk about realistic solutions, from injectables and resurfacing lasers to hormone therapy and everyday skincare that actually supports your skin at this stage of life. This episode is not about “fixing” your face. It's about finally getting answers to the questions so many women are asking and doing so with a sense of clarity. Key Takeaways: Skin loses up to 30% of its collagen in the first five years after menopause. Estrogen is important for your skin's hydration, elasticity, thickness, and glow. It's normal to experience acne, dryness, sagging, and texture changes but that doesn't mean you have to just accept it. Bio-stimulatory injectables, topical actives, laser treatments, and even hormone replacement therapy can all play a role when used wisely and intentionally. Aging is not a decline. It's a transition that deserves support, not shame. Pooja H. Rambhia, MD, is a board-certified dermatologist with specialized fellowship training in cosmetic dermatology and laser surgery. She practices at UnionDerm in New York City and Greenwich, CT, providing comprehensive dermatologic care and specializing in laser treatments, injectables, and facial and body contouring for all skin types. Dr. Rambhia completed her medical training at Case Western Reserve University and dermatology residency at Zucker School of Medicine/Northwell Health, where she served as Chief Resident. She then completed the prestigious American Society for Dermatologic Surgery Fellowship at UnionDerm with Dr. Anne Chapas. Committed to advancing the field of dermatology, Dr. Rambhia has published numerous peer-reviewed articles in leading journals and presented her research at major national conferences including the American Academy of Dermatology and the American Society for Dermatologic Surgery. Her expertise has been featured in major media outlets including Vogue, Allure, Marie Claire, InStyle, Elle and The New York Times. Dr. Rambhia is dedicated to delivering personalized, natural-looking results while combining artistry with the latest scientific innovations in aesthetic dermatology. Follow Dr. Rambhia here: https://www.instagram.com/drpoojarambhia/?hl=en https://www.instagram.com/unionderm/?hl=en https://www.unionderm.com/ Download my Free Guide 'In My Perimenopause Era'

On today's episode we're focusing on wearable technology for athlete performance, recovery and injury prevention with Dr. Jacob Calcei, an orthopedic surgeon at University Hospitals in Cleveland and team physician for the Cleveland Browns. We'll start off our discussion today with an article titled “Wearable Performance Devices in Sports Medicine” from the January 2016 issue of Sports Health. The authors review the rapid rise of wearable sensor technologies in athletics, highlighting their ability to track real-time physiologic and movement data for optimizing performance and reducing injury risk. These tools can provide valuable insights into workloads, biomechanics, and fatigue, supporting tailored training programs and early injury prevention strategies. While wearable devices have shown promise, evidence for their effectiveness in professional sports remains limited, and further research is needed to validate accuracy, develop standardized training protocols, and address practical challenges such as reliability and usability.Then, from the January 2020 issue of Sports Heath, we review an article titled “Does Overexertion Correlate With Increased Injury? The Relationship Between Player Workload and Soft Tissue Injury in Professional American Football Players Using Wearable Technology.” This study investigates whether sudden increases in training load, as measured by wearable GPS and accelerometry technology, are associated with higher rates of soft tissue injury in professional American football players.  The authors analyzed two NFL seasons and found that injured players experienced significantly greater spikes in workload during the week of injury compared to the prior month. Specifically,  they found that those exceeding an acute-to-chronic workload ratio (ACR) of 1.6 being 1.5 times more likely to sustain an injury. The effect was particularly pronounced in the preseason, when workloads were higher and hamstring injuries were most common. The findings suggest that rapid workload increases predispose athletes to soft tissue injury, while consistent training loads may offer a protective effect. The authors conclude that monitoring player workload with wearable technology could help medical and training staff design safer, more individualized training regimens to reduce injury risk.We are joined today by Dr. Jacob Calcei, a board-certified orthopedic sports medicine physician and shoulder surgeon at University Hospitals and an assistant professor of Orthopedic Surgery at Case Western Reserve University School of Medicine. He is a team physician for the Cleveland Browns as well as several local high schools. Dr. Calcei has published extensively on a variety of sports medicine topics, has a particular interest in injury prevention and finding ways that we can make sports safer while optimizing athlete performance. So, we're very excited to have him join us today.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Ivy Zelman is one of the most respected voices in American housing, co-founder of Zelman & Associates, and now Executive Vice President at Walker & Dunlop, which acquired her firm in 2021 as the leading institutional research, advisory, and investment banking firm dedicated exclusively to the U.S. housing industry.Over the last three decades, Ivy has built a reputation for bold, contrarian analysis—famously calling the top of the housing market in 2005 and the bottom in 2012—moments that cemented her as a rare analyst unafraid to speak truth to consensus. That conviction has earned her numerous accolades, including recognition in Barron's 100 Most Influential Women in U.S. Finance for four consecutive years and induction into the California Homebuilding Foundation's Hall of Fame.In our conversation, we trace Ivy's journey from falling into equity research to taking the entrepreneurial leap in 2007, founding Zelman & Associates amid the looming financial crisis. We explore her approach to research and analysis—blending proprietary surveys with a nationwide network of builders, brokers, and lenders—to consistently separate signal from noise.We reflect on her evolution as a leader and entrepreneur, the culture she has cultivated with a team that has stayed by her side for decades, her love of Cleveland, and what it means to pay it forward today through teaching and mentorship as an Adjunct Professor of Finance at Case Western Reserve University, her memoir Gimme Shelter, and much more.00:00:00 - Catalytic Moments in Finance00:08:25 - Recognizing Blind Spots in Research00:11:27 - The Entrepreneurial Inclination00:11:55 - Building Conviction and Confidence00:15:54 - Vision for Success00:17:21 - Detective Work in Research00:18:45 - Cultivating a Strong Network00:22:20 - The Importance of Asking the Right Questions00:25:13 - Reconciliation with Reality00:26:35 - Navigating Market Sentiment00:28:13 - The Evolution of Zellman Associates00:30:38 - Personal Growth as an Entrepreneur00:34:06 - Leadership and Team Development00:36:01 - Maintaining Intellectual Honesty Post-Acquisition00:37:39 - Understanding the Value of Research00:39:15 - Cleveland's Unique Perspective00:42:10 - Paying It Forward and Mentorship00:45:38 - Lessons for the Next Generation00:47:23 - Contrarian Views on Market Trends00:49:17 - Balancing Work and Family Life00:51:20 - Hidden Gem-----LINKS:https://www.linkedin.com/in/ivy-zelman-64304616b/https://www.zelmanassociates.com/https://www.amazon.com/Gimme-Shelter-Skills-Street-Trailblazer/dp/1737709929-----SPONSOR:Roundstone InsuranceRoundstone Insurance is proud to sponsor Lay of The Land. Founder and CEO, Michael Schroeder, has committed full-year support for the podcast, recognizing its alignment with the company's passion for entrepreneurship, innovation, and community leadership.Headquartered in Rocky River, Ohio, Roundstone was founded in 2005 with a vision to deliver better healthcare outcomes at a more affordable cost. To bring that vision to life, the company pioneered the group medical captive model — a self-funded health insurance solution that provides small and mid-sized businesses with greater control and significant savings.Over the past two decades, Roundstone has grown rapidly, creating nearly 200 jobs in Northeast Ohio. The company works closely with employers and benefits advisors to navigate the complexities of commercial health insurance and build custom plans that prioritize employee well-being over shareholder returns. By focusing on aligned incentives and better health outcomes, Roundstone is helping businesses save thousands in Per Employee Per Year healthcare costs.Roundstone Insurance — Built for entrepreneurs. Backed by innovation. Committed to Cleveland.-----Stay up to date by signing up for Lay of The Land's weekly newsletter — sign up here.Past guests include Justin Bibb (Mayor of Cleveland), Pat Conway (Great Lakes Brewing), Steve Potash (OverDrive), Umberto P. Fedeli (The Fedeli Group), Lila Mills (Signal Cleveland), Stewart Kohl (The Riverside Company), Mitch Kroll (Findaway — Acquired by Spotify), and over 200 other Cleveland Entrepreneurs.Connect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Lay of The Land on X @podlayofthelandhttps://www.jeffreys.page/

Your liver could be silently struggling right now and the good news is, you can turn it around. In this episode, I dive deep into the topic of metabolic dysfunction-associated steatotic liver disease, also known as fatty liver disease. I explain what it is, why the medical community updated the name, and why it matters for long-term health. I highlight who is most at risk, including people with obesity, diabetes, high blood pressure, or high cholesterol and why the condition is often called a “silent disease” since many don't realize they have it. I also break down the potential dangers if it progresses, from inflammation to cirrhosis, and share the encouraging news that it's often reversible with lifestyle changes. My goal is to empower listeners to protect their liver and overall health with small, sustainable changes.  Take control of your health and tune in to this episode to learn how you can prevent, reverse, and protect your liver from fatty liver disease with simple, sustainable steps!   Episode Highlights: What MASLD is and why the name changed from NAFLD Why fatty liver disease is becoming more common and who's most at risk Signs, symptoms, and why it's often called a “silent disease” Potential complications, including inflammation, fibrosis, and cirrhosis How fatty liver is diagnosed through blood tests, imaging, or scans Lifestyle strategies to reverse or prevent progression  The role of managing diabetes, cholesterol, and blood pressure in protecting liver health FDA-approved medications such as Wegovy and others that may help in treatment Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

What if a scan could do more than show you a picture, what if it could tell you a story about what's happening inside a child's body, in real time?That's exactly what Dr. Chris Flask is working to make possible.Dr. Flask is a Professor of Radiology, Biomedical Engineering, and Pediatrics at Case Western Reserve University and University Hospitals of Cleveland. He's at the forefront of an exciting transformation in medical imaging, one that could change the way we care for children with rare genetic diseases like cystic fibrosis (CF) and polycystic kidney disease (PKD).“Our goal is to turn imaging, instead of just image creation, into data,” says Dr. Flask. “We want to create numbers. So we can say, this is what's going on in the lungs. And when we put these patients on modulator therapies, we can see a 10 percent improvement in their lung disease. And similar responses in the pancreas, the liver, and the gut. That's our goal—quantifying it through this fingerprinting methodology.”This approach, MRI fingerprinting, is a revolutionary leap forward. Developed over the past decade at Case Western's MRI center, it's fast, accurate, and most importantly for kids: it requires no sedation, no radiation, and no contrast agents. Each image slice takes just 15 seconds, making it safer and more accessible for the most vulnerable patients.Dr. Flask's work is supported by the NIH, the Cystic Fibrosis Foundation, and an extraordinary 42-year collaboration with Siemens MRI. Together, they're paving the way for multi-center clinical trials using this technology to better understand disease progression and therapy outcomes.This episode is all about the intersection of science, innovation, and compassion, and the powerful impact of data-driven care.We're honored to welcome Dr. Flask to the show, although he prefers we call him Chris. You won't want to miss this deep dive into what's next for pediatric imaging and precision medicine.Share with anyone who's passionate about medical innovation, pediatric health, or rare disease research. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

You can also watch the video version of this episode on dvm360.com Alice Jeromin, RPh, DACVD—Before earning her DVM degree from The Ohio State University, Jeromin graduated from the University of Toledo with a BS in Pharmacy and practiced as a hospital pharmacist. She completed her veterinary dermatology residency with Patrick Breen and dermatopathology training at Procter & Gamble, Miami Valley Labs, as well as a fellowship in human dermatology at Metro Health Medical Center, Cleveland, Ohio with Bryan Davis. Jeromin is currently an adjunct professor at Case Western Reserve University, lecturer at Northeast Ohio College of Pharmacy, and former practice owner of Veterinary Allergy & Dermatology, Inc. She is a former member-at-large on AVMA's Council on Biologicals and Therapeutics as chairman of the supplements and compounding committees. Along with publishing in human and veterinary journals, she authored the dermatology chapter in “Pharmacotherapeutics for Veterinary Dispensing”. Her interests include human-animal comparative dermatology and skin lipid research with publications in both areas.  Because of her pharmacist background of counseling patients, she is a strong believer in client education and maintains her website, www.purrfectpet.com, for clients to be educated with evidence-based information as well as an upcoming podcast "Speaking of Pets" The podcast is geared toward pet owners of allergic pets to provide them with accurate, evidence-based information.

Announcing Season Seven of Parenting Musically! Parenting Musically is supported by Case Western Reserve University. Season seven is co-hosted by Dr. Lisa Huisman Koops and Dr. George Blake, faculty members at Case Western Reserve University.

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/lgbtq-studies

TransGenre (Cambridge UP, 2025) is a reconsideration of genre theory in long-form fiction through transgender minor literature in the US and Canada. Using four genre sites (the road novel, the mourning novel, the chosen family novel, and the archival novel), this Element considers how the minoritized becomes the minoritarian through deterritorializing generic conventions in fiction to its own ends. In so doing, TransGenre proposes narrative reading practices as strategies of the minor to subvert, transgress, and reappropriate the novel's genealogy and radical future prospects. A range of fiction published in the last decade is deployed as largely self-theorizing, generating its own epistemological, thematic, and formal innovations and possibilities, revealing cisheteronormative underpinnings of generic categories and turning them in on themselves. Aaron Hammes holds a PhD in English from the CUNY Graduate Center, and was most recently the Virginia and Walter Nord Postdoctoral Fellow in the Humanities at Case Western Reserve University. Dr. Hammes has published on sex work, transgender literature, and prison abolition in South Atlantic Review, Women's Studies Quarterly, the Routledge Handbook of Transgender Literature, Journal of Feminist Scholarship, and GLQ. Their first monograph, TransGenre, (Cambridge, 2025) is an exploration of genre theory and contemporary transgender minor literature. Atalia Israeli-Nevo is an anthropology PhD student at the University of Texas at Austin.

Did you know that nearly one in three people with obesity may have fatty liver disease without even knowing it? In this episode, I talk about groundbreaking news in obesity and liver health, focusing on the FDA's recent approval of WeGovy to treat metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced fibrosis. I share a personal story about a friend who once struggled with fatigue, abnormal liver tests, and fatty liver disease, highlighting how limited treatment options used to be. I explain what MASH is, why it's so serious, and how common it is, especially among people with obesity and metabolic syndrome.  Furthermore, I dive into the ESSENCE trial, which showed that WeGovy not only improved liver inflammation and scarring but in some cases even reversed the disease, all while emphasizing that it works best when combined with lifestyle changes like healthy eating and regular activity.  Don't miss this episode where I break down the latest breakthrough in liver and weight loss care that could change your health journey!   Episode Highlights: FDA approval of WeGovy for treating MASH with fibrosis The ESSENCE trial results showing improvements in liver health Understanding what MASH is and why it's so common Importance of combining medication with lifestyle changes Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode, we're joined by Dr. Pooja Rambhia, a board-certified dermatologist with specialized training in cosmetic dermatology and laser surgery. Dr. Rambhia attended Case Western Reserve University School of Medicine, where she completed an NIH research fellowship, followed by dermatology residency at Northwell and a cosmetic-laser fellowship at Union Dermatology in New York City, where she now practices. Tune in as we dive into her career journey, the role of mentorship, advice for students interested in dermatology, and how she balances clinical practice with aesthetics and innovation. We hope you enjoy!Connect with Dr. Rambhia:Instagram: @drpoojarambhiaTikTok: @thatskindoc.pooja---DIGA Instagram: @⁠⁠derminterest⁠⁠Today's Host, Katelyn: @⁠⁠katsteng---For questions, comments, or future episode suggestions, please reach out to us via email at ⁠⁠⁠⁠⁠⁠derminterestpod@gmail.com⁠⁠⁠⁠⁠⁠---Music: "District Four" Kevin MacLeod (⁠⁠⁠⁠⁠⁠incompetech.com⁠⁠⁠⁠⁠⁠) Licensed under Creative Commons:By Attribution 4.0 License:⁠⁠⁠⁠⁠⁠ http://creativecommons.org/licenses/by/4.0

In this episode of Perimenopause: Head to Toe, Dr. Rachel Pope welcomes Dr. Danette Conklin, PhD, a Clinical and Health Psychologist and Assistant Professor at Case Western Reserve University School of Medicine. Dr. Conklin shares her expertise on the intersection of behavioral health, weight management, and midlife transitions, including perimenopause and menopause.As Director of Behavioral Health Services for both surgical and non-surgical weight management programs at University Hospitals Cleveland Medical Center, Dr. Conklin has a unique perspective on how psychological and biological factors influence health during midlife. She has also contributed to establishing menopause clinics in Cleveland, helping women navigate the physical and emotional changes of this life stage.We discuss: How behavioral health intersects with perimenopause and menopause Managing weight, mood, and lifestyle changes during midlife The role of psychology in supporting cardiovascular and metabolic health Strategies for navigating stress, sleep, and emotional shifts How to advocate for yourself and your care during midlife transitions Practical ways to support wellness, including the use of non-prescription supplements like MiM, which are designed to help with peri- and post-menopause symptomsWith her extensive experience on national committees and advisory boards, including The Menopause Society and the American Society for Metabolic and Bariatric Surgery, Dr. Conklin provides practical guidance for women seeking to thrive during this transformative stage of life.

Should machines make decisions in the warfield? Can the “move fast and break things” motto of Silicon Valley be applied in the military? Join us in an interview with Dr. Shannon French about ethics in the military in the age of artificial intelligence. Dr. French is the Inamori Professor in Ethics and the Director of the Inamori International Center for Ethics and Excellence at Case Western Reserve University and an advisor to the members of the US and Allied militaries and various US defense and DoD-funded research agencies.Meet the speakers here: https://aiandfaith.org/aif-podcast/ai-in-military-decision-making/Views and opinions expressed by podcast guests are their own and do not necessarily reflect the view of AI and Faith or any of its leadership.Production: Pablo Salmones and Penny YuenHost: Pablo SalmonesGuest: Shannon E. FrenchEditing: Isabelle BraconnotMusic from #UppbeatLicense code: 1ZHLF7FMCNHU39

Hester M. Peirce, Commissioner at the U.S. Securities and Exchange Commission, discusses the SEC's new approach to regulation under the Crypto Task Force. She details the commission's efforts to foster a healthy, regulated crypto market and the importance of cross-border cooperation in enforcement. Key Takeaways:  How the SEC is providing input for lawmakers on new regulations, and taking feedback from businesses in the industry Shifting from an enforcement-focused mindset to providing regulatory clarity The importance of regulatory frameworks that protect investors while still allowing innovation Ways to collaborate with the U.S. Congress on legislation Guest Bio: Hester M. Peirce was appointed by President Donald J. Trump to the U.S. Securities and Exchange Commission, and was sworn in on January 11, 2018. Earlier this year, Commissioner Peirce was designated as the leader of the SEC's Crypto Task Force. Prior to joining the SEC, Commissioner Peirce conducted research on the regulation of financial markets, and was a Senior Counsel on the U.S. Senate Committee on Banking, Housing, and Urban Affairs. Commissioner Peirce earned her bachelor's degree in Economics from Case Western Reserve University, and her JD from Yale Law School. ---------------------------------------------------------------------------------------- About this Show: The Brave Technologist is here to shed light on the opportunities and challenges of emerging tech. To make it digestible, less scary, and more approachable for all! Join us as we embark on a mission to demystify artificial intelligence, challenge the status quo, and empower everyday people to embrace the digital revolution. Whether you're a tech enthusiast, a curious mind, or an industry professional, this podcast invites you to join the conversation and explore the future of AI together. The Brave Technologist Podcast is hosted by Luke Mulks, VP Business Operations at Brave Software—makers of the privacy-respecting Brave browser and Search engine, and now powering AI everywhere with the Brave Search API. Music by: Ari Dvorin Produced by: Sam Laliberte  

Sometimes the most tempting quick fixes, like eating only one type of food, can actually set you back on your health journey. In this episode, I explored the viral TikTok trend known as the watermelon diet, breaking down why it may seem tempting but is ultimately risky and unsustainable. I shared a story about a friend who was pressured to try it and explained how social media can create unrealistic expectations and comparisons. While watermelon has health benefits like hydration, low calories, and vitamins, I highlighted the dangers of relying on it exclusively—nutrient deficiencies, loss of muscle mass, blood sugar spikes, digestive issues, and unsustainable weight loss. I emphasized that real progress comes from balance: eating a variety of nutrient-rich foods, staying consistent with healthy habits, moving in enjoyable ways, managing stress, and prioritizing rest. Most importantly, I reminded listeners to focus on their own journey, celebrate small wins, and not let social media dictate their worth.   Tune in to discover the truth behind viral diet trends and learn healthier, lasting ways to reach your goals.   Episode Highlights: The rise of the viral watermelon diet on social media Why extreme mono fruit diets are risky and unsustainable Health benefits of watermelon in moderation Nutrient deficiencies and health risks linked to the diet The role of comparison and pressure from social media Science-backed strategies for balanced, long-term weight loss Importance of mindset, consistency, and celebrating small wins Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

A Sea of Wealth: The Omani Empire and the Making of an Oceanic Marketplace (U California Press, 2025) is a sweeping retelling of the Omani position in the Indian Ocean. Here the reign of Oman's longest-serving ruler, Saʿid bin Sultan, offers a keyhole through which we can peer to see the entangled histories of Arabia and the Gulf, South Asia, and East Africa in the Omani Empire. In centering this empire, Nicholas P. Roberts shows how Arabs, Africans, and Asians actively shaped the conditions of commercial engagement in the Western Indian Ocean, uniting the empire's domains into a single oceanic marketplace in which Europeans and Americans had to accede if they wished to succeed. Drawing upon sources in three languages from four continents, A Sea of Wealth is a vivid narrative full of colorful characters that upturns many conventional understandings of our modern world. Nicholas P. Roberts was formerly Assistant Professor of History at Norwich University and the Howell Fellow for Arabian Peninsula and Gulf Studies at the University of Virginia. He is currently earning a JD at Case Western Reserve University. Ahmed Yaqouob AlMaazmi is an Assistant Professor of History at the United Arab Emirates University, with interests in the intersections of empire, science, slavery, law, environmental infrastructures, and material culture in the Arabian Peninsula and the wider Indian Ocean world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

A Sea of Wealth: The Omani Empire and the Making of an Oceanic Marketplace (U California Press, 2025) is a sweeping retelling of the Omani position in the Indian Ocean. Here the reign of Oman's longest-serving ruler, Saʿid bin Sultan, offers a keyhole through which we can peer to see the entangled histories of Arabia and the Gulf, South Asia, and East Africa in the Omani Empire. In centering this empire, Nicholas P. Roberts shows how Arabs, Africans, and Asians actively shaped the conditions of commercial engagement in the Western Indian Ocean, uniting the empire's domains into a single oceanic marketplace in which Europeans and Americans had to accede if they wished to succeed. Drawing upon sources in three languages from four continents, A Sea of Wealth is a vivid narrative full of colorful characters that upturns many conventional understandings of our modern world. Nicholas P. Roberts was formerly Assistant Professor of History at Norwich University and the Howell Fellow for Arabian Peninsula and Gulf Studies at the University of Virginia. He is currently earning a JD at Case Western Reserve University. Ahmed Yaqouob AlMaazmi is an Assistant Professor of History at the United Arab Emirates University, with interests in the intersections of empire, science, slavery, law, environmental infrastructures, and material culture in the Arabian Peninsula and the wider Indian Ocean world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/middle-eastern-studies

A Sea of Wealth: The Omani Empire and the Making of an Oceanic Marketplace (U California Press, 2025) is a sweeping retelling of the Omani position in the Indian Ocean. Here the reign of Oman's longest-serving ruler, Saʿid bin Sultan, offers a keyhole through which we can peer to see the entangled histories of Arabia and the Gulf, South Asia, and East Africa in the Omani Empire. In centering this empire, Nicholas P. Roberts shows how Arabs, Africans, and Asians actively shaped the conditions of commercial engagement in the Western Indian Ocean, uniting the empire's domains into a single oceanic marketplace in which Europeans and Americans had to accede if they wished to succeed. Drawing upon sources in three languages from four continents, A Sea of Wealth is a vivid narrative full of colorful characters that upturns many conventional understandings of our modern world. Nicholas P. Roberts was formerly Assistant Professor of History at Norwich University and the Howell Fellow for Arabian Peninsula and Gulf Studies at the University of Virginia. He is currently earning a JD at Case Western Reserve University. Ahmed Yaqouob AlMaazmi is an Assistant Professor of History at the United Arab Emirates University, with interests in the intersections of empire, science, slavery, law, environmental infrastructures, and material culture in the Arabian Peninsula and the wider Indian Ocean world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/african-studies

A Sea of Wealth: The Omani Empire and the Making of an Oceanic Marketplace (U California Press, 2025) is a sweeping retelling of the Omani position in the Indian Ocean. Here the reign of Oman's longest-serving ruler, Saʿid bin Sultan, offers a keyhole through which we can peer to see the entangled histories of Arabia and the Gulf, South Asia, and East Africa in the Omani Empire. In centering this empire, Nicholas P. Roberts shows how Arabs, Africans, and Asians actively shaped the conditions of commercial engagement in the Western Indian Ocean, uniting the empire's domains into a single oceanic marketplace in which Europeans and Americans had to accede if they wished to succeed. Drawing upon sources in three languages from four continents, A Sea of Wealth is a vivid narrative full of colorful characters that upturns many conventional understandings of our modern world. Nicholas P. Roberts was formerly Assistant Professor of History at Norwich University and the Howell Fellow for Arabian Peninsula and Gulf Studies at the University of Virginia. He is currently earning a JD at Case Western Reserve University. Ahmed Yaqouob AlMaazmi is an Assistant Professor of History at the United Arab Emirates University, with interests in the intersections of empire, science, slavery, law, environmental infrastructures, and material culture in the Arabian Peninsula and the wider Indian Ocean world. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/south-asian-studies

A Sea of Wealth: The Omani Empire and the Making of an Oceanic Marketplace (U California Press, 2025) is a sweeping retelling of the Omani position in the Indian Ocean. Here the reign of Oman's longest-serving ruler, Saʿid bin Sultan, offers a keyhole through which we can peer to see the entangled histories of Arabia and the Gulf, South Asia, and East Africa in the Omani Empire. In centering this empire, Nicholas P. Roberts shows how Arabs, Africans, and Asians actively shaped the conditions of commercial engagement in the Western Indian Ocean, uniting the empire's domains into a single oceanic marketplace in which Europeans and Americans had to accede if they wished to succeed. Drawing upon sources in three languages from four continents, A Sea of Wealth is a vivid narrative full of colorful characters that upturns many conventional understandings of our modern world. Nicholas P. Roberts was formerly Assistant Professor of History at Norwich University and the Howell Fellow for Arabian Peninsula and Gulf Studies at the University of Virginia. He is currently earning a JD at Case Western Reserve University. Ahmed Yaqouob AlMaazmi is an Assistant Professor of History at the United Arab Emirates University, with interests in the intersections of empire, science, slavery, law, environmental infrastructures, and material culture in the Arabian Peninsula and the wider Indian Ocean world. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week as the negotiations for a Global Plastic Treaty fail in Geneva, Switzerland over a cap on plastic production, we look at the undue influence of the fossil fuel and plastic industries. False solutions to the climate crisis, and now the plastic pollution crisis, are part of an industry playbook to misinform the public and deflect from actual solutions. In the case of plastics, it's promoting plastic recycling that doesn't actually work. In our latest, we talk with researchers Davis Allen and Rebecca John to discuss industry strategies to undermine any progress on curbing plastic pollution. Bios//Rebecca John is a Research Fellow at the Climate Investigations Center. She is also a freelance journalist and award-winning documentary film maker. As a Producer and Director of the acclaimed “Extreme Oil” / “Curse of Oil” series for PBS /BBC her work was awarded a Cine Golden Eagle for News Analysis. Other award-winning and nominated series and films include “Churchill” for PBS & ITV, “The Secret World of Richard Nixon” for The History Channel/BBC and “Ambush In Mogadishu” for PBS Frontline/ BBC (winner of the Edward R. Murrow Overseas Press Club of America ‘Best Documentary on Foreign Affairs Award'). Davis Allen is a Senior Investigative Researcher at the Center for Climate Integrity, where he identifies and compiles evidence of the fossil fuel industry's historical — and ongoing — deception. Prior to joining CCI, Davis completed a PhD in History at Case Western Reserve University.-----------------------------------------------------------Outro- "Green and Red Blues" by MoodyLinks//+ "‘Maddening' Proof Plastics Industry Knew Recycling Was False Solution in 1974, New Document Shows" (https://bit.ly/45QWEHE)+ "The Fraud of Plastic" (https://bit.ly/4lt3Xd6)+ Plastic pollution talks fail as negotiators in Geneva reject draft treaties (https://bit.ly/45xljzF)

In this episode, we speak with Dr. Damour about the emotional lives of teenagers. We pay especial attention to the pressures that both genders feel yet how those may be manifested differently across genders, at times. Dr. Damour unpacks parent-child relationships, especially the mother-daughter relationship, and the role of identification in that relationship as girls mature. We also discuss how research methods may not always allow for the identification of areas of concern for boys.  Dr. Lisa Damour is the author of three New York Times best sellers: Untangled, Under Pressure, and The Emotional Lives of Teenagers. She co-hosts the Ask Lisa podcast, works in collaboration with UNICEF, and is recognized as a thought leader by the American Psychological Association. Dr. Damour is also a regular contributor to The New York Times and CBS News. Dr. Damour serves as a Senior Advisor to the Schubert Center for Child Studies at Case Western Reserve University and has written numerous academic papers, chapters, and books related to education and child development. She maintains a clinical practice and also speaks to schools, professional organizations, and corporate groups around the world on the topics of child and adolescent development, family mental health, and adult well-being. Dr. Damour graduated with honors from Yale University and worked for the Yale Child Study Center before earning her doctorate in Clinical Psychology at the University of Michigan. She has been a fellow at Yale's Edward Zigler Center in Child Development and Social Policy and the University of Michigan's Power Foundation. She and her husband are the proud parents of two daughters. To learn more about Dr. Damour and her work please visit https://drlisadamour.com/ and follow her on instagram @lisa.damour 

Today's episode is going to focus on lateral augmentation procedures to supplement ACL reconstruction, including lateral extraarticular tenodesis versus anterolateral ligament reconstruction.We are joined today by two outstanding guests!  Dr. Alan Getgood is the Chief of Surgery at Aspetar and Adjunct Professor of orthopedic surgery at the University of Western Ontario. He is a clinician scientist who has secured over $9 million in peer-reviewed and industry-funded grants to build his research program focused on complex knee reconstruction. Dr. Getgood is member of the AOSSM Board of Directors, Herodicus Society, ACL Study Group and was the program chair for the ISAKOS Biennial Congress last month.Dr. James Voos is a Professor of orthopedic surgery at Case Western Reserve University School of Medicine and Chairman of the orthopedics department at University Hospitals. He successfully launched the UH Drusinsky Sports Medicine Institute and served at the Chief of Sports Medicine and Medical Director. Dr. Voos is the head team physician for the Cleveland Browns, Medical Director for the Cleveland Ballet and current President of the NFL Physicians Society.So, without further ado, let's get to the Exhibit Hall!

Research endowments and Trump administration.  EriK Jensen, Case Western Reserve University, Civitas Institute 1888 STANFORD MANSION

Research endowments and Trump administration.  EriK Jensen, Case Western Reserve University, Civitas Institute continued 1900

In this engaging episode of the Healthcare Education Transformation Podcast, host Dr. F Scott Feil talks to Blaze Hirsch, a dedicated nurse manager and educator with a wealth of experience across various healthcare settings. The conversation delves into Blaze's fascinating journey through the nursing landscape, highlighting his education at Case Western Reserve University and his subsequent roles in various hospitals throughout the United States. The episode zeroes in on the challenges faced by nursing professionals and students alike, from the burden of student debt to the necessity for real-world clinical preparedness. A significant part of the discussion is Blaze's emphasis on the transformation in nursing education and his optimism for scholarship programs that alleviate financial burdens on future nurses.The dialogue also explores broader themes within the healthcare education system, like the importance of interdisciplinary education, the challenges of staffing shortages, and the potential for artificial intelligence to revolutionize healthcare training. Dr. Feil and Blaze discuss the gaps in current educational methods and share insights into methods for improving learning experiences through simulation, experiential learning, and mentorship. Blaze highlights the importance of increasing faculty for healthcare education and calls for legislative support to incentivize educational roles. This episode is a call to professionals and educators to collaborate across fields for better healthcare outcomes, underscoring the need for innovative solutions to the ongoing challenges within nursing education.

August is Psoriasis Awareness Month. This annual observance aims to educate the public about psoriasis, a chronic autoimmune condition that affects millions worldwide, and to support those living with it. Joining me today to talk about psoriasis is Rosanne Paul, DO. Dr Paul is an assistant professor of dermatology at the Case Western Reserve University School of Medicine.

When it comes to weight loss, the scale isn't the only thing that changes—your reflection and self-image often transform too. In this episode, I talk about a topic gaining attention in the media and social circles: "Ozempic face" and the emotional and physical effects of rapid weight loss, especially for those using GLP-1 medications like Wegovy, Zepbound, or Ozempic. I share a story about a friend who hesitated to increase her dosage due to concerns about skin changes, which opened the door to a larger discussion on body image during weight loss. I explain that these facial and skin changes—such as sagging, wrinkles, or looking more tired—aren't exclusive to medication use but are common with any significant weight loss, especially as we age.  Furthermore, I walk through ways to manage these concerns, like slowing down weight loss, prioritizing resistance training and protein, staying hydrated, considering aesthetic treatments, and most importantly, shifting focus from appearance to overall health. I emphasize the importance of support, tuning out unsolicited comments, and curating a healthier social media feed.  If you're navigating weight loss and struggling with body image changes like "Ozempic face," listen to this empowering episode for real talk, expert tips, and compassionate support on your journey.   Episode Highlights: What “Ozempic face” really means and why it happens Emotional impact of rapid weight loss and changing appearance How to manage body image concerns during weight loss Practical tips: strength training, hydration, and pacing weight loss Cosmetic treatment options and when to consider them The role of social media in shaping unrealistic expectations Reframing the focus from appearance to overall health and wellness Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Jacob Phillips is Co-Founder of Lombard Finance, the company building the full stack of Bitcoin infrastructure needed to bring Bitcoin Capital Markets on-chain and pioneer behind LBTC - the fastest staking protocol to reach $2B TVL. Jacob previously served as Partner at Polychain Capital leading venture investments and governance, and in Product & Strategy at Perennial Labs. Graduated from Case Western Reserve University with degrees in Economics and Computer Science.In this conversation, we discuss:- NYC is the crypto capital of the world- Working at Polychain Capital- BTC ecosystem and markets- Lombard history and LBTC accomplishments- Bitcoin Capital Markets introduction- Lombard roadmap to accelerating Bitcoin Capital Markets adoption- Connecting Bitcoin liquidity to external ecosystems and markets- How Lombard securitizes your BTC- Integrating BTC tooling onchainLombard FinanceWebsite: www.lombard.financeX: @Lombard_Finance Discord: discord.gg/2HG7G69twcJacob PhillipsX: @JacobPPhillipsLinkedIn: Jacob Phillips---------------------------------------------------------------------------------This episode is brought to you by PrimeXBT.PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.  PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions. Code: CRYPTONEWS50 This promotion is available for a month after activation. Click the link below: PrimeXBT x CRYPTONEWS50

More people than ever are turning to medicine for weight loss, but how do you know if it's right for you? In this episode, I dive into the hot topic of weight loss medications and tackle the myths, science, and facts behind them. As a board-certified obesity medicine specialist, I explain who qualifies for medications like Wegovy, Zepbound, and others, how they work, and why obesity is a chronic condition, not a personal failure. I will walk you through the medical, hormonal, and genetic factors that influence treatment, outline FDA guidelines, and share how I assess whether a patient is a good candidate. I also discuss common misconceptions, long-term use, and tips for having an informed conversation with your doctor. Because remember, It's not about shortcuts, it's about finding the right tools to improve your health and quality of life. Tune in to learn the truth about weight loss medications, debunk common myths, and find out if they're the right fit for your health journey.   Episode Highlights: Who qualifies for weight loss medications FDA-approved options Common myths debunked about weight loss drugs How GLP-1 medications work and their long-term role in obesity treatment Key factors doctors assess before prescribing Contraindications and who should not take these medications How to talk to your doctor about medical weight loss options Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Send us a textDid you know that laundry is the #1 source of microplastic pollution? With every load of laundry, millions of tiny plastic particles come off our synthetic clothes, down the drain, and into our waterways. In this episode, we speak with Max Pennington, Co-Founder and CEO of CLEANR. Max and his partners may have the solution to plastic pollution we've been looking for. His Cleveland-based company recently launched a patented filter that captures up to 90% of all microplastics from your washing machine before they enter the drain. Max developed this breakthrough technology with fellow engineering students Chip Miller and David Dillman within the Sears think[box], an innovation lab at Case Western Reserve University. Their VORTX filter design was inspired by the gills of fish, specifically by the way manta rays and basking sharks filter feed. This biomimicry-based design creates a vortex that keeps the filter from clogging while effectively capturing harmful microplastics. These young entrepreneurs recently launched their company CLEANR, with a filter that easily attaches to any washing machine. Hear how Max and his partners plan to bring this technology to market. Their CLEANR filter is currently available as an external washing machine attachment for $299. The ultimate goal is to integrate it directly into washing machines, making microplastic filtration as standard as lint traps in dryers. The company is also exploring applications beyond laundry, including whole-home water filtration to protect against microplastics entering our bodies through drinking water. Capturing microplastics before they enter our waterways could be a real game-changer, especially if supported by legislators and policymakers. Would they go for it? Max thinks so. Already, five U.S. states have introduced legislation requiring microplastic filters on washing machines, with similar momentum building in Europe. With synthetic fibers from our clothing accounting for 35% of all plastic pollution in our water systems, the implications extend far beyond environmental protection. Recent studies have found alarming connections between microplastics in the human body and increased risk of heart disease and other health conditions. These plastic particles have been discovered in human blood, brains, and even the placentas of newborn babies. With an estimated 22 million pounds of microplastic particles entering the Great Lakes annually, the Cleaner team aims to make Cleveland "ground zero in the fight against microplastic pollution," tackling it one laundry load at a time.Learn More:About our Guest, Max Pennington, Co-Founder and CEO of CLEANRAbout CLEANRAbout buying a CLEANR Filter About Sears think[box] About microplastics and laundry About Microplastics and the Great Lakes  Follow us: https://www.facebook.com/ecospeaksclehttps://www.instagram.com/ecospeakscleContact us:hello@ecospeakscle.com